Intestinal transplantation (ITx) is the definitive treatment for intestinal failure but has the highest rejection rate among solid organ transplants, requiring high doses of immunosuppression with high rates of infection, graft-versus-host disease, and malignancy. Transplant tolerance would overcome the need for long-term immunosuppression. Using non-myeloablative conditioning, our laboratory has developed a novel swine model of hematopoietic stem cell transplantation (HSCT) that produces durable mixed chimerism (MC) and immune tolerance without toxicity. We investigated whether durable MC would promote tolerance of subsequently transplanted donor-matched intestinal allografts without immunosuppression. Using miniature swine with defined MHC, we performed HSCT across an MHC-Class-I haplotype mismatch. Immunosuppression was stopped by day 45. MC was evaluated by flow cytometry, and mixed lymphocyte reaction (MLR) assays were used to evaluate cellular responses. Subsequently, orthotopic ITx was performed without immunosuppression using a donor that was MHC-matched to the HSCT donor. Recipients were observed for four weeks and euthanized for tissue collection and mechanistic assays. After HSCT, the recipients developed durable multilineage MC and apparent deletional tolerance. After ITx, recipients showed no clinical or histological signs of rejection, and chimerism was unchanged. These results demonstrate the potential value of generating durable MC to achieve transplant tolerance.

中文翻译：

---

持久的混合嵌合体可能允许随后的无免疫抑制肠道移植 - 一项原理验证研究。


肠移植 （ITx） 是肠衰竭的确定性治疗方法，但在实体器官移植中排斥反应率最高，需要高剂量的免疫抑制，感染率高，移植物抗宿主病和恶性肿瘤的发生率高。移植耐受性将克服长期免疫抑制的需要。使用非清髓性条件反射，我们的实验室开发了一种新型的造血干细胞移植 （HSCT） 猪模型，可产生持久的混合嵌合体 （MC） 和免疫耐受，而无毒性。我们研究了持久的 MC 是否会在没有免疫抑制的情况下促进后续移植的供体匹配的肠道同种异体移植物的耐受性。使用具有定义 MHC 的微型猪，我们在 MHC-Class I 单倍型错配中进行了 HSCT。免疫抑制在第 45 天停止。通过流式细胞术评估 MC，并使用混合淋巴细胞反应 （MLR） 测定来评估细胞反应。随后，使用与 HSCT 供体 MHC 匹配的供体进行原位 ITx，无需免疫抑制。观察受体 4 周，并对组织采集和机制测定实施安乐死。HSCT 后，受者出现持久的多系 MC 和明显的缺失耐受性。在 ITx 之后，受者没有表现出排斥的临床或组织学体征，嵌合体没有变化。这些结果表明了生成耐用的 MC 以实现移植耐受性的潜在价值。